• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TRIBE2 研究中肝转移局限的转移性结直肠癌患者的放射组学特征的预后价值。

The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study.

机构信息

Unit of Oncology, University Hospital of Pisa, Pisa, Italy & Department of Translational Research & New Technologies in Medicine & Surgery, University of Pisa, Via Roma 67, 56126, Pisa, Italy.

Academic Radiology, Department of Translational Research & New Technologies in Medicine & Surgery, University of Pisa, Via Roma 67, 56126, Pisa, Italy.

出版信息

Future Oncol. 2023 Jul;19(23):1601-1611. doi: 10.2217/fon-2023-0406. Epub 2023 Aug 14.

DOI:10.2217/fon-2023-0406
PMID:37577810
Abstract

Evaluating the prognostic role of radiomic features in liver-limited metastatic colorectal cancer treated with first-line therapy at baseline and best response among patients undergoing resection. Among patients enrolled in TRIBE2 (NCT02339116), the association of clinical and radiomic data, extracted by SOPHiA-DDM™ with progression-free and overall survival (OS) in the overall population and with disease-free survival/postresection OS in those undergoing resection was investigated. Among 98 patients, radiomic parameters improved the prediction accuracy of our model for OS (area under the curve: 0.83; sensitivity: 0.85; specificity: 0.73; accuracy: 0.78), but not progression-free survival. Of 46 resected patients, small-distance high gray-level emphasis was associated with shorter disease-free survival and high gray-level zone emphasis/higher kurtosis with shorter postresection OS. Radiomic features should be implemented as tools of outcome prediction for liver-limited metastatic colorectal cancer.

摘要

评估基线时接受一线治疗和最佳反应的肝转移结直肠癌患者的放射组学特征在接受切除术的患者中的预后作用。在 TRIBE2 研究(NCT02339116)中,调查了通过 SOPHiA-DDM™提取的临床和放射组学数据与总人群的无进展生存和总生存(OS)以及接受切除术患者的无疾病生存/术后 OS 的相关性。在 98 名患者中,放射组学参数提高了我们的 OS 预测模型的准确性(曲线下面积:0.83;灵敏度:0.85;特异性:0.73;准确性:0.78),但不能预测无进展生存期。在 46 例接受切除术的患者中,小距离高灰度区强调与较短的无疾病生存期相关,高灰度区强调/更高峰度与较短的术后 OS 相关。放射组学特征应作为肝转移结直肠癌预后预测的工具。

相似文献

1
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study.TRIBE2 研究中肝转移局限的转移性结直肠癌患者的放射组学特征的预后价值。
Future Oncol. 2023 Jul;19(23):1601-1611. doi: 10.2217/fon-2023-0406. Epub 2023 Aug 14.
2
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials.骨转移与接受双联或三联化疗加贝伐珠单抗治疗的转移性结直肠癌患者的预后较差相关:TRIBE 和 TRIBE2 试验的亚分析。
ESMO Open. 2022 Dec;7(6):100606. doi: 10.1016/j.esmoop.2022.100606. Epub 2022 Oct 31.
3
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.采用不可切除肝转移瘤的放射组学特征对接受 FOLFIRI 和贝伐珠单抗治疗的结直肠癌患者进行早期评估,预测其预后。
Gut. 2020 Mar;69(3):531-539. doi: 10.1136/gutjnl-2018-316407. Epub 2019 May 17.
4
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.FOLFOXIRI 联合贝伐珠单抗治疗肝转移结直肠癌的疗效:西北肿瘤协作组的临床研究汇总分析。
Eur J Cancer. 2017 Mar;73:74-84. doi: 10.1016/j.ejca.2016.10.028. Epub 2016 Dec 13.
5
Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy.肿瘤钙化与接受贝伐珠单抗联合化疗的转移性结直肠癌患者的生存改善相关。
Future Oncol. 2022 Jul;18(22):2453-2464. doi: 10.2217/fon-2021-1422. Epub 2022 Jun 17.
6
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. upfront FOLFOXIRI 联合贝伐珠单抗和进展后再引入与 mFOLFOX6 联合贝伐珠单抗后序贯 FOLFIRI 联合贝伐珠单抗治疗转移性结直肠癌患者(TRIBE2):一项多中心、开放标签、3 期、随机、对照临床试验。
Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.
7
An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.三氟尿苷/替匹嘧啶单药治疗及联合贝伐单抗或免疫检查点抑制剂用于转移性结直肠癌患者的探索:一项真实世界研究
Clin Colorectal Cancer. 2023 Mar;22(1):76-84. doi: 10.1016/j.clcc.2022.11.005. Epub 2022 Dec 1.
8
Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study.结直肠癌肝转移患者对含贝伐单抗化疗的形态学反应:WJOG4407G III期研究的事后分析
Medicine (Baltimore). 2020 Sep 4;99(36):e22060. doi: 10.1097/MD.0000000000022060.
9
A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series.三氟尿苷/替匹嘧啶联合贝伐珠单抗治疗转移性结直肠癌的系统评价和荟萃分析:来自真实世界系列的证据。
Curr Oncol. 2023 May 24;30(6):5227-5239. doi: 10.3390/curroncol30060397.
10
Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.替氟嘧啶-替匹嘧啶联合贝伐珠单抗对比卡培他滨联合贝伐珠单抗作为无法接受强化治疗的转移性结直肠癌患者一线治疗方案(SOLSTICE):一项随机、开放标签的3期研究
Lancet Gastroenterol Hepatol. 2023 Feb;8(2):133-144. doi: 10.1016/S2468-1253(22)00334-X. Epub 2022 Dec 2.

引用本文的文献

1
Prognostic Factors in Colorectal Liver Metastases: An Exhaustive Review of the Literature and Future Prospectives.结直肠癌肝转移的预后因素:文献综述及未来展望
Cancers (Basel). 2025 Jul 31;17(15):2539. doi: 10.3390/cancers17152539.
2
Differentiating low tumor burden from oligometastatic disease in colorectal cancer: a call for individualized therapeutic approaches.区分结直肠癌低肿瘤负荷与寡转移疾病:呼吁采用个体化治疗方法。
ESMO Open. 2025 Aug 12;10(8):105520. doi: 10.1016/j.esmoop.2025.105520.
3
The Role of Artificial Intelligence on Tumor Boards: Perspectives from Surgeons, Medical Oncologists and Radiation Oncologists.
人工智能在肿瘤委员会中的作用:外科医生、肿瘤内科医生和放射肿瘤医生的观点。
Curr Oncol. 2024 Aug 27;31(9):4984-5007. doi: 10.3390/curroncol31090369.
4
Machine Learning and Radiomics Analysis for Tumor Budding Prediction in Colorectal Liver Metastases Magnetic Resonance Imaging Assessment.用于结直肠癌肝转移磁共振成像评估中肿瘤芽生预测的机器学习与影像组学分析
Diagnostics (Basel). 2024 Jan 9;14(2):152. doi: 10.3390/diagnostics14020152.